Key Points
- CEO Clay Siegall purchased 7,278 shares of Immunome on December 19 at an average price of $20.48, a $149,053 transaction that raised his stake to 860,525 shares (a 0.85% increase) valued at roughly $17.6 million.
- The company reported a quarterly loss (EPS of $(0.65), missing estimates) with extremely negative profitability metrics (net margin -1,687.08%, ROE -76.5%), and analysts forecast a -2.21 EPS for the year.
- Analysts maintain a consensus rating of Moderate Buy with an average target of $30.09 (individual targets range roughly $21–$40), while institutional investors own about 44.6% of the stock and several large funds recently increased positions.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay Siegall acquired 7,278 shares of the business's stock in a transaction on Friday, December 19th. The stock was acquired at an average price of $20.48 per share, for a total transaction of $149,053.44. Following the acquisition, the chief executive officer owned 860,525 shares of the company's stock, valued at approximately $17,623,552. This trade represents a 0.85% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Immunome Trading Up 2.8%
Shares of NASDAQ:IMNM opened at $22.03 on Tuesday. The stock has a fifty day simple moving average of $17.84 and a two-hundred day simple moving average of $12.82. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $25.30. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -7.47 and a beta of 2.17.
Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, equities research analysts predict that Immunome, Inc. will post -2.21 EPS for the current year.
Analysts Set New Price Targets
Several research firms recently commented on IMNM. Leerink Partners set a $40.00 price objective on Immunome in a research report on Monday, December 15th. Truist Financial started coverage on shares of Immunome in a research note on Monday, December 1st. They set a "buy" rating and a $36.00 target price on the stock. Wedbush reaffirmed an "outperform" rating and set a $21.00 price target on shares of Immunome in a report on Friday, November 7th. Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a research note on Saturday, November 22nd. Finally, The Goldman Sachs Group began coverage on shares of Immunome in a report on Monday, September 22nd. They set a "buy" rating and a $26.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $30.09.
Check Out Our Latest Stock Report on IMNM
Hedge Funds Weigh In On Immunome
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Redmile Group LLC boosted its stake in shares of Immunome by 11.0% during the 1st quarter. Redmile Group LLC now owns 5,361,187 shares of the company's stock worth $36,081,000 after acquiring an additional 533,161 shares during the last quarter. Vanguard Group Inc. lifted its position in Immunome by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,893,626 shares of the company's stock valued at $57,304,000 after purchasing an additional 368,674 shares in the last quarter. EcoR1 Capital LLC grew its holdings in Immunome by 5.2% during the first quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company's stock valued at $27,454,000 after purchasing an additional 200,000 shares during the period. Geode Capital Management LLC grew its holdings in Immunome by 6.7% during the second quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company's stock valued at $17,305,000 after purchasing an additional 117,523 shares during the period. Finally, Woodline Partners LP increased its position in Immunome by 69.0% in the first quarter. Woodline Partners LP now owns 1,657,729 shares of the company's stock worth $11,157,000 after buying an additional 676,804 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.
About Immunome
(
Get Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
